Soleno Therapeutics (SLNO) Competitors $46.13 -1.29 (-2.72%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$46.72 +0.59 (+1.28%) As of 02/21/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SLNO vs. GKOS, STVN, BLCO, INSP, NARI, NVST, PRCT, IRTC, WRBY, and LIVNShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Glaukos Stevanato Group Bausch + Lomb Inspire Medical Systems Inari Medical Envista PROCEPT BioRobotics iRhythm Technologies Warby Parker LivaNova Soleno Therapeutics (NASDAQ:SLNO) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings. Is SLNO or GKOS more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Glaukos' net margin of -42.43%. Glaukos' return on equity of -18.99% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -61.99% -55.21% Glaukos -42.43%-18.99%-11.47% Which has more risk & volatility, SLNO or GKOS? Soleno Therapeutics has a beta of -1.46, suggesting that its stock price is 246% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Do analysts prefer SLNO or GKOS? Soleno Therapeutics currently has a consensus target price of $71.20, suggesting a potential upside of 54.35%. Glaukos has a consensus target price of $163.25, suggesting a potential upside of 29.53%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Soleno Therapeutics is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Glaukos 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92 Which has stronger valuation & earnings, SLNO or GKOS? Soleno Therapeutics has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$38.99M-$3.32-13.89Glaukos$314.71M22.08-$134.66M-$3.02-41.73 Does the media refer more to SLNO or GKOS? In the previous week, Glaukos had 21 more articles in the media than Soleno Therapeutics. MarketBeat recorded 24 mentions for Glaukos and 3 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.35 beat Glaukos' score of 0.29 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 5 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in SLNO or GKOS? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by company insiders. Comparatively, 6.4% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SLNO or GKOS? Glaukos received 139 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 72.16% of users gave Soleno Therapeutics an outperform vote while only 65.03% of users gave Glaukos an outperform vote. CompanyUnderperformOutperformSoleno TherapeuticsOutperform Votes31172.16% Underperform Votes12027.84% GlaukosOutperform Votes45065.03% Underperform Votes24234.97% SummarySoleno Therapeutics and Glaukos tied by winning 9 of the 18 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$3.40B$5.77B$8.98BDividend YieldN/A1.65%4.78%3.85%P/E Ratio-13.8916.9626.4618.82Price / SalesN/A74.90453.2580.30Price / CashN/A45.9944.0437.47Price / Book8.943.867.634.64Net Income-$38.99M$92.00M$3.18B$245.69M7 Day Performance-6.18%4.50%-1.91%-2.66%1 Month Performance-4.75%9.09%-0.19%-2.15%1 Year Performance-5.10%12.27%16.70%12.90% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.5423 of 5 stars$46.13-2.7%$71.20+54.3%-5.1%$2.04BN/A-13.8930News CoveragePositive NewsGKOSGlaukos4.4083 of 5 stars$153.06+4.6%$151.08-1.3%+35.8%$8.44B$314.71M-50.68780Earnings ReportAnalyst UpgradeInsider TradeNews CoverageGap DownSTVNStevanato Group1.2373 of 5 stars€19.49+2.2%N/A-32.8%$5.90B$1.17B41.475,635BLCOBausch + Lomb3.6226 of 5 stars$16.44-1.2%$20.25+23.2%-5.3%$5.79B$4.15B-15.6513,300Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINSPInspire Medical Systems4.8377 of 5 stars$184.73-1.3%$228.82+23.9%-4.2%$5.54B$624.80M172.651,011Insider TradeNARIInari Medical1.687 of 5 stars$79.93flat$68.00-14.9%+40.0%$4.68B$493.63M-59.211,300NVSTEnvista3.5455 of 5 stars$21.59+0.3%$20.21-6.4%-6.5%$3.71B$2.51B-3.3312,800PRCTPROCEPT BioRobotics3.2739 of 5 stars$67.61-2.4%$97.86+44.7%+28.3%$3.53B$199.84M-34.67430Positive NewsIRTCiRhythm Technologies1.1312 of 5 stars$112.11-0.1%$108.45-3.3%+6.8%$3.51B$492.68M-23.072,000Earnings ReportAnalyst ForecastNews CoverageWRBYWarby Parker2.5521 of 5 stars$25.70-2.7%$21.77-15.3%+71.6%$2.61B$669.77M-95.193,491Upcoming EarningsAnalyst ForecastGap UpLIVNLivaNova3.5845 of 5 stars$47.68+0.1%$69.17+45.1%-16.5%$2.59B$1.15B113.522,900Upcoming Earnings Related Companies and Tools Related Companies Glaukos Alternatives Stevanato Group Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives Inari Medical Alternatives Envista Alternatives PROCEPT BioRobotics Alternatives iRhythm Technologies Alternatives Warby Parker Alternatives LivaNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLNO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
